• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

Baxalta

Baxter rises after Street-beating preliminary 4Q sales results

January 13, 2020 By Sean Whooley

Baxter (NYSE:BAX) shares were up today after the company reported preliminary net sales for the fourth quarter of fiscal 2019 that topped the Wall Street consensus. The Deerfield, Ill.-based company posted net sales of $3 billion for the fourth quarter, marking 7% growth on a reported basis and 9% growth on an operational basis. That number […]

Filed Under: Business/Financial News, Featured, MassDevice Earnings Roundup Tagged With: Baxalta, Baxter, Sanofi

Report: Medtech M&A values up sharply in 1st half of 2016

July 7, 2016 By Brad Perriello

The cumulative value of mergers & acquisitions in the medical device space jumped nearly 50% during the 1st half of 2016, even as the total number of deals fell at a double-digit clip, according to MergerMarket. There were some 394 deals worth a total of $74.5 billion during H1 2016, according to the report, marking […]

Filed Under: Mergers & Acquisitions, Wall Street Beat Tagged With: Abbott, Baxalta, Baxter, Shire Plc., stjudemedical

Baxter boosts Baxalta share exchange offer

May 5, 2016 By Brad Perriello

Baxter (NYSE:BAX) said today that its raising the size of its offer to exchange its own shares for those of its Baxalta (NYSE: BXLT) pharmaceuticals spinout ahead of its acquisition by Shire (NSDQ:SHPGY). Baxter cut its stake in Baxalta in January from 19.4% to 13.8%. In March, Deerfield, Ill.-based Baxter exchanged about 59.4 million Baxalta shares at $39.40 apiece, leave […]

Filed Under: Funding Roundup, Pharmaceutical, Wall Street Beat Tagged With: Baxalta, Baxter

Baxter to further trim stake in Baxalta ahead of $32B Shire buyout

March 17, 2016 By Brad Perriello

Baxter (NYSE:BAX) plans to further trim its stake in Baxalta (NYSE:BXLT), the biopharm business it spun out last year, reducing its ownership to 5.1% ahead of Baxalta’s $32 billion takeover by Shire (NSDQ:SHPGY). In January, Baxter cut its stake in Baxalta from 19.4% to 13.8%. In the latest move, Deerfield, Ill.-based Baxter will exchange about 59.4 million Baxalta shares […]

Filed Under: Funding Roundup, Mergers & Acquisitions, Pharmaceutical Tagged With: Baxalta, Baxter, Shire Plc.

Baxalta wants Shire to boost $30B takeover bid

August 19, 2015 By Brad Perriello

(Reuters) — Baxalta (NYSE:BXLT),  the spinout of Baxter‘s (NYSE:BAX) biopharmaceuticals division, wants Shire (NSDQ:SHPGY) to improve on its $30 billion bid significantly before it will engage in talks, while its Dublin-based rival could sweeten its offer if it gets to see the U.S. biotech company’s books, according to sources on both sides. Both camps are pushing hard behind […]

Filed Under: Mergers & Acquisitions, Pharmaceutical Tagged With: Abbott, AbbVie, Baxalta, Baxter, Shire Plc.

ConMed ripe for M&A | The week in medtech M&A

May 27, 2015 By MassDevice Contributors Network

Analyst: ConMed ripe for M&A spree May 19, 2015 by Fink Densford ConMed, in the middle of an under-appreciated turnaround, could be poised to augment its growth via selective acquisitions, according to Leerink Partners analyst Richard Newitter. Newitter, who upgraded CNMD shares to “outperform” and boosted the price target to $64 from $60, wrote in […]

Filed Under: Mergers & Acquisitions, News Well Tagged With: Apax Partners, Baxalta, Baxter, becton dickinson, CareFusion Corp., ConMed Corp., cyberonics, Gen-Probe Inc., Hologic, INC Research Inc., JP Morgan Chase, Kendle International Inc., Kinetic Concepts Inc., Lincare, Linde, Perella Weinberg Partners, Sorin Group

Baxter looks to growth post-Baxalta spinout

May 20, 2015 By Mark Hollmer Leave a Comment

Baxter looks to growth post-Baxalta spinout

Baxter (NYSE:BAX) said it plans to boost its sales and margin growth after the planned July 1 spinout of its biopharmaceutical division as Baxalta.

Filed Under: Mergers & Acquisitions, News Well, Pharmaceutical, Wall Street Beat Tagged With: Baxalta, Baxter

Baxter logs Q1 sales, earnings beats

April 23, 2015 By Brad Perriello Leave a Comment

Baxter logs Q1 sales, earnings beats

Investors bid shares of Baxter (NYSE:BAX) up this morning after the healthcare giant reported sales and earnings that beat expectations on Wall Street and its own prior guidance, despite declines for both numbers.

Filed Under: MassDevice Earnings Roundup, News Well Tagged With: 2015, Baxalta, Baxter, Q1

Baxter biopharm spinout Baxalta’s R&D is Cambridge-bound

September 30, 2014 By Alex Soule Leave a Comment

Baxter biopharm spinout Baxalta's R&D is Cambridge-bound

Filed Under: News Well, Pharmaceutical, Wall Street Beat Tagged With: Baxalta, Baxter

Baxter names its pharma spinout: Baxalta

September 11, 2014 By Arezu Sarvestani

Baxter names its pharma spinout: Baxalta

Baxter (NYSE:BAX) crept a little closer to spinning out its biopharmaceuticals division into an independent entity by giving the company a name: Baxalta.

Filed Under: Mergers & Acquisitions, News Well, Pharmaceutical Tagged With: Baxalta, Baxter

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy